Search results for "Anti-cancer drugs"

showing 4 items of 4 documents

Selective Cytotoxic Activity of Prodigiosin@halloysite Nanoformulation

2020

Prodigiosin, a bioactive secondary metabolite produced by Serratia marcescens, is an effective proapoptotic agent against various cancer cell lines, with little or no toxicity toward normal cells. The hydrophobicity of prodigiosin limits its use for medical and biotechnological applications, these limitations, however, can be overcome by using nanoscale drug carriers, resulting in promising formulations for target delivery systems with great potential for anticancer therapy. Here we report on prodigiosin-loaded halloysite-based nanoformulation and its effects on viability of malignant and non-malignant cells. We have found that prodigiosin-loaded halloysite nanotubes inhibit human epithelia…

0301 basic medicineHistologylcsh:BiotechnologyBiomedical EngineeringBioengineering02 engineering and technologyhalloysite nanotubesengineering.materialHalloysiteProdigiosin03 medical and health scienceschemistry.chemical_compoundcomet assaylcsh:TP248.13-248.65Cytotoxic T cellcancerOriginal Researchgenotoxic effectanti-cancer drugsbiologyChemistryBioengineering and Biotechnology021001 nanoscience & nanotechnologybiology.organism_classificationmalignant cellsComet assay030104 developmental biologyprodigiosinDrug deliveryToxicitySerratia marcescensdrug deliveryCancer researchengineering0210 nano-technologyDrug carrierBiotechnologyFrontiers in Bioengineering and Biotechnology
researchProduct

Antiproliferative and pro-apoptotic activity of melatonin analogues on melanoma and breast cancer cells

2017

// Giuliana Gatti 1, * , Valeria Lucini 2, * , Silvana Dugnani 2 , Angela Calastretti 1 , Gilberto Spadoni 3 , Annalida Bedini 3 , Silvia Rivara 4 , Marco Mor 4 , Gianfranco Canti 1 , Francesco Scaglione 2 and Annamaria Bevilacqua 1 1 Department of Medical Biotechnology and Translational Medicine, Universita degli Studi di Milano, Milan, Italy 2 Department of Oncology and Hemato-oncology, Universita degli Studi di Milano, Milan, Italy 3 Department of Biomolecular Sciences, Universita degli Studi di Urbino “Carlo Bo”, Urbino, Italy 4 Department of Food and Drug, Universita degli Studi di Parma, Parma, Italy * Authors contributed equally to this work Correspondence to: Annamaria Bevilacqua, e…

0301 basic medicineanti-cancer drugs; breast cancer; melanoma; melatonin analogues; melatonin receptorsPharmacologyMelatonin03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerIn vivomelatonin receptorsmelanomaMedicineCytotoxic T cellReceptoranti-cancer drugsbusiness.industryMelanomamelatonin analoguesmedicine.disease030104 developmental biologyOncologyApoptosis030220 oncology & carcinogenesisCancer cellbusinesshormones hormone substitutes and hormone antagonistsResearch Papermedicine.drugOncotarget
researchProduct

3-Aryl-2-[1H-benzotriazol-1-yl]acrylonitriles: a novel class of potent tubulin inhibitors.

2011

During a screening for compounds that could act against Mycobacterium tuberculosis, a series of new cellular antiproliferative agents was identified. The most cytotoxic molecules were evaluated against a panel of human cell lines derived from hematological and solid human tumors. In particular, (E)-2-(1H-benzo[d] [1,2,3]triazol-1-yl)-3-(4-methoxyphenyl)acrylonitrile (1) was found to be of a potency comparable to etoposide and greater than 6-mercaptopurine in all cell lines tested. Accordingly, a synthesis of a new series of (E)-2-(5,6-dichloro-1H-benzo[d] [1,2,3]triazol-1-yl)-3-(4-R-phenyl)acrylonitriles was conducted in order to extend the studies of structure-activity relationship (SAR) f…

Models MolecularMagnetic Resonance SpectroscopyMolecular modelStereochemistryAnti-cancer drugsBinding CompetitiveGas Chromatography-Mass SpectrometryAnti-cancer drugchemistry.chemical_compoundStructure-Activity RelationshipTubulinAnti-cancer drugs; drug design and development; computer assisted drug designDrug DiscoveryK562 CellmedicineStructure–activity relationshipHumansdrug design and developmentPharmacologybiologyAcrylonitrileChemistryArylOrganic ChemistryCell Cyclecomputer assisted drug designGeneral MedicineCell cycleTriazolesTubulinPodophyllotoxinCell cultureTubulin Binding Agentbiology.proteinTriazoleColchicineK562 CellsHumanmedicine.drugEuropean journal of medicinal chemistry
researchProduct

4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.

2014

Hsp90 is considered an interesting therapeutic target for anticancer drug development. Here we describe a new class of 4,5,6,7-tetrahydro-isoxazolo-[4,5-c]-pyridine compounds. A small library of derivatives has been synthesized and investigated. Some reported compounds show interesting properties combining both notable binding to Hsp90 and potent cell growth inhibitory activity. N-5 substitution with a 2,4 resorcinol carboxamide appears crucial for activity. Moreover, a derivative bearing a hydroxamic acid residue bound to C-3 amide portion was found to inhibit both Hsp90 and HDAC6.

Spectrometry Mass Electrospray IonizationMagnetic Resonance Spectroscopymedicine.drug_classStereochemistryPyridinesCarboxamideApoptosisResorcinolAnti-cancer drugschemistry.chemical_compoundResidue (chemistry)AmideDrug DiscoveryHeat shock protein 90 Anti-cancer drugs 4567-Tetrahydro-isoxazolo-[45-c]- pyridinesmedicineCytotoxic T cellHumansHeat shock protein 90HSP90 Heat-Shock ProteinsPharmacologyHydroxamic acidChemistryCell growthOrganic ChemistryGeneral MedicineNuclear magnetic resonance spectroscopy4 5 6 7-Tetrahydro-isoxazolo-[4 5-c]-pyridinesFlow CytometrySettore CHIM/08 - Chimica Farmaceuticahsp90Settore BIO/14 - Farmacologia4 5 6 7-Tetrahydro-isoxazolo-[4 5-c]-pyridines; Anti-cancer drugs; Heat shock protein 90;K562 CellsCell DivisionEuropean journal of medicinal chemistry
researchProduct